Mergers & Acquisitions

Zuellig Pharma on its acquisition of Cialis and Alimta from Eli Lilly for eight ASEAN markets.

Versanis Bio on its acquisition by Eli Lilly and Company for up to $1.925 billion.

Haystack Oncology on its acquisition by Quest Diagnostics for up to $450 million.

Vaccitech plc on its acquisition of Avidea Technologies, Inc. for approximately $40 million in cash and equity, plus potential payments upon achievement of milestones.

Thrive Earlier Detection Corp. on its acquisition by Exact Sciences Corporation for up to $2.15 billion.

Unum Therapeutics on the sale of its BOXR (Bolt-on Chimeric Receptor) technology for approximately $11.5 million.

Unum Therapeutics on its acquisition of KIQ LLC and concurrent PIPE investment to raise $104 million.

Avadel Legacy Pharmaceuticals, a wholly owned subsidiary of Avadel Pharmaceuticals (Ireland), on the sale of its hospital product assets for approximately $40 million.

Alnylam Pharmaceuticals on a $100 million equity financing closed in connection with its $2 billion strategic financing collaboration with Blackstone.

CRISPR Therapeutics on a series of transactions by which CRISPR acquired 100% of the partnership interests of Casebia Therapeutics.

BeiGene on its $2.7 billion share sale as part of a global strategic collaboration with Amgen.

BlueRock Therapeutics on its acquisition by Bayer AG for up to $1 billion.

Ultragenyx Pharmaceuticals Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.

Venture Financings

Beta Bionics on its $63 million Series B2 financing and its $57 Series C financing.

Versanis Bio on its $70 million Series A financing.

OrbiMed as co-lead investor on the $40 million Series A financing of Gennao Bio.

Amylyx Pharmaceuticals on its $135 million Series C financing.

Karuna Therapeutics on its $82 million Series B financing.

Thrive Earlier Detection Corp. on its $110 million Series A financing.

Capital Markets

AlloVir on its $317.7 million IPO, $100 million at-the-market offering, $126.6 million registered direct offering, and $75 million follow-on public offering.

Cerevel Therapeutics on its $350 million follow-on public offering, $600 million public offering of common stock and concurrent private placement of 144A convertible senior notes, and $250 million at-the-market offering.

Esperion Therapeutics on its $280 million 144A offering, $250 million at-the-market offering, $225 million follow-on public offering, and $57 million registered direct offering.

Karuna Therapeutics on its $100 million IPO, $250 million and $287.5 million follow-on public offerings, and $150 million at-the-market offering.

Bluebird bio on its $75 million private placement financing in connection with its spinout of 2seventy bio.

Kymera Therapeutics on its $257 million follow-on public offering.